SCHEMBL15375503

SCHEMBL15375503

Cc1cc(OCc2ccccc2C(O)C(N)=O)cc(C)c1C

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CD274 Q9NZQ7 9/20 0.44
MAOB P27338 3/20 0.41
SCN9A Q15858 1/20 0.40
KDM4E B2RXH2 1/20 0.38
PARP10 Q53GL7 4/20 0.37
PARP15 Q460N3 2/20 0.37
PARP14 Q460N5 2/20 0.37
ESR1 P03372 1/20 0.37
TP53 P04637 1/20 0.37
POLB P06746 1/20 0.37
APEX1 P27695 1/20 0.37
MAPK1 P28482 1/20 0.37
ESR2 Q92731 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
BCL2 P10415 1/20 0.37
MCL1 Q07820 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15375321 0.88 FABP4 (0.46) CD274MAOBESR1TP53POLB
SCHEMBL15375385 0.88 PARP10 (0.42) MAOBSCN9APARP10PARP15PARP14
SCHEMBL15402163 0.87 MAOB (0.41) CD274MAOBESR1TP53POLB
SCHEMBL15401831 0.86 MAOB (0.40) CD274MAOBESR1TP53POLB
SCHEMBL15375571 0.84 PARP10 (0.47) MAOBSCN9AKDM4EPARP10PARP15
SCHEMBL15375524 0.83 KDM4E (0.50) MAOBSCN9AKDM4EPARP10PARP15
SCHEMBL15375555 0.83 SMN1; SMN2 (0.44) MAOBMAPK1L3MBTL1
SCHEMBL27855165 0.83 SCN9A (0.38) CD274MAOBSCN9AKDM4EPARP10
SCHEMBL15402066 0.82 FFAR1 (0.41) MAOBPOLBMAPK1L3MBTL1
SCHEMBL15375369 0.82 PTGDR2 (0.43) CD274MAOBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2682382-B1 Method for Producing Phenylacetamide Compound SUMITOMO CHEMICAL CO (JP) 2016-11-23 EP disclosed
EP-2662352-B1 Method for Producing Phenylacetamide Compound SUMITOMO CHEMICAL CO (JP) 2016-11-09 EP disclosed
CN-103588657-B The manufacture method of phenylacetyl amines 住友化学株式会社 2016-06-22 CN disclosed
EP-2397459-B1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND SUMITOMO CHEMICAL CO (JP) 2015-12-16 EP disclosed
EP-2682382-A2 Method for Producing Phenylacetamide Compound Sumitomo Chemical Company, Limited (JP) 2014-01-08 EP disclosed
US-8624062-B2 Method for producing phenylacetamide compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-01-07 US disclosed
EP-2662352-A2 Method for Producing Phenylacetamide Compound Sumitomo Chemical Company, Limited (JP) 2013-11-13 EP disclosed
EP-2397459-A1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND Sumitomo Chemical Company, Limited (JP) 2011-12-21 EP disclosed
US-20110295035-A1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110295035-A1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND MRPL21, AADAC, ARSA CD274 4797/4885MAOB 1169/4885SCN9A 2592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.